Skip to main content
. 2021 Feb 11;10(1):507–520. doi: 10.1007/s40121-021-00409-7

Table 5.

Sensitivity analyses on pneumonia and otitis media changes attributable to pneumococcal conjugate vaccines

ICERs with percent of otitis media declines attributable to PCVs
100% 50% 25%
ICERs with percent of pneumonia changes attributable to PCVs 10% $8622 $24,895 $37,611
25% $1722 $9471 $14,450
50% 13vPCV cost saving $1400 $3712

ICER incremental cost-effectiveness ratio, PCV pneumococcal conjugate vaccine